2019年—2020年胰腺癌放射治疗新进展

任刚; 王颖杰

doi:10.3969/j.issn.1001-5256.2021.03.048

2019年—2020年胰腺癌放射治疗新进展

DOI: 10.3969/j.issn.1001-5256.2021.03.048

任刚,
王颖杰^,

空军特色医学中心放射治疗科，北京 100142

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：任刚负责文献检索，撰写论文；王颖杰负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
任刚(1980—)，男，副主任医师，博士，主要从事胰腺恶性肿瘤放射治疗研究

通信作者:
王颖杰，wangyj9999@163.com

中图分类号: R735.9
计量
- 文章访问数: 1155
- HTML全文浏览量: 600
- PDF下载量: 118
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-25
- 录用日期: 2020-09-27
- 出版日期: 2021-03-20

Advances in radiotherapy for pancreatic cancer from 2019 to 2020

Gang REN,
Yingjie WANG^,

Department of Radiotherapy, Air Force Medical Center, Beijing 100142, China

摘要

摘要: 随着放疗设备、影像技术、人工智能等方面的迅速发展，放疗已进入精准时代。放疗是胰腺癌治疗的重要手段之一，近期在相关放疗理念、技术模式方面进展很快。结合目前放疗领域专家所关注的胰腺癌放疗技术新进展、放疗剂量模式改变等热点问题，回顾近期相关文献加以总结分析，归纳提示多模态影像对指导胰腺癌放疗有重要作用，放疗剂量模式向高剂量少分次方向发展，新辅助放疗的作用得到进一步证实，多药联合的强力化疗方案是胰腺癌放疗的主要联合方式。
- 胰腺肿瘤 /
- 放射疗法 /
- 综合疗法
Abstract: With the rapid development of radiotherapy equipment, imaging technology, and artificial intelligence, radiotherapy has entered the era of precision therapy. Radiotherapy is one of the important methods for the treatment of pancreatic cancer, and rapid progress has been made in related concepts and technical models of radiotherapy in recent years. With reference to the latest advances in radiotherapy technology and the change of radiotherapy dose mode, which the experts in the field of radiotherapy are concerned with, this article reviews and analyzes recent articles and points out that multimodal images play an important role in guiding radiotherapy for pancreatic cancer, and the dose mode of radiotherapy develops to high-dose hypofractionated radiotherapy. The effect of neoadjuvant radiotherapy has been further confirmed, and strong chemotherapy with the combination of multiple drugs is the main radiotherapy regimen for pancreatic cancer.
- Pancreatic Neoplasms /
- Radiotherapy /
- Combined Modality Therapy

HTML全文

参考文献(28)

[1]	XU XH, ZENG XY, WANG LJ, et al. The disease burden of pancreatic cancer in China in 1990 and 2017[J]. Chin J Epidemiol, 2019, 40(9): 1084-1088. 徐晓慧, 曾新颖, 王黎君, 等. 1990年与2017年中国胰腺癌疾病负担分析[J]. 中华流行病学杂志, 2019, 40(9): 1084-1088.
[2]	PILGRIM C, TE MARVELDE L, STUART E, et al. Population-based analysis of treatment patterns and outcomes for pancreas cancer in Victoria[J]. ANZ J Surg, 2020, 90(9): 1677-1682. DOI: 10.1111/ans.15721
[3]	CARAVATTA L, CELLINI F, SIMONI N, et al. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: A multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers[J]. Acta Oncol, 2019, 58(4): 439-447. DOI: 10.1080/0284186X.2018.1546899
[4]	DIFFENDERFER ES, VERGINADIS Ⅱ, KIM MM, et al. Design, implementation, and in vivo validation of a novel proton FLASH radiation therapy system[J]. Int J Radiat Oncol Biol Phys, 2020, 106(2): 440-448. DOI: 10.1016/j.ijrobp.2019.10.049
[5]	BOURHIS J, SOZZI WJ, JORGE PG, et al. Treatment of a first patient with FLASH-radiotherapy[J]. Radiother Oncol, 2019, 139: 18-22. DOI: 10.1016/j.radonc.2019.06.019
[6]	XIANG M, HEESTAND GM, CHANG DT, et al. Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database[J]. Radiother Oncol, 2020, 143: 101-107. DOI: 10.1016/j.radonc.2020.01.007
[7]	TCHELEBI LT, LEHRER EJ, TRIFILETTI DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer(CRiSP): An international systematic review and meta-analysis[J]. Cancer, 2020, 126(10): 2120-2131. DOI: 10.1002/cncr.32756
[8]	BERTHOLET J, HUNT A, DUNLOP A, et al. Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer[J]. Clin Transl Radiat Oncol, 2019, 16: 21-27. DOI: 10.1016/j.ctro.2019.03.001
[9]	AZIZ H, ZEESHAN M, JIE T, et al. Neoadjuvant chemoradiation therapy is associated with adverse outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer[J]. Am Surg, 2019, 85(11): 1276-1280. DOI: 10.1177/000313481908501136
[10]	KAMARAJAH SK, BUNDRED JR, BOYLE C, et al. Impact of neoadjuvant therapy on post-operative pancreatic fistula: A systematic review and meta-analysis[J]. ANZ J Surg, 2020, 90(11): 2201-2210. DOI: 10.1111/ans.15885
[11]	THANIKACHALAM K, DAMARLA V, SEIXAS T, et al. Neoadjuvant Phase Ⅱ trial of chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer[J]. Am J Clin Oncol, 2020, 43(6): 435-441. DOI: 10.1097/COC.0000000000000688
[12]	TRAN NH, SAHAI V, GRIFFITH KA, et al. Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 106(1): 124-133. DOI: 10.1016/j.ijrobp.2019.08.057
[13]	EGUCHI H, TAKEDA Y, TAKAHASHI H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2019, 26(13): 4498-4505. DOI: 10.1245/s10434-019-07735-8
[14]	VERSTEIJNE E, SUKER M, GROOTHUIS K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16): 1763-1773. DOI: 10.1200/JCO.19.02274
[15]	LUTSYK M, BEN-YOSEF R. The role of radiotherapy in resected r0/r+ pancreatic cancer: A real-life single-institution experience[J]. Am J Clin Oncol, 2020, 43(3): 187-192. DOI: 10.1097/COC.0000000000000653
[16]	KAMARAJAH SK, SONNENDAY CJ, CHO CS, et al. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: A propensity-matched National Cancer Database (NCDB) Analysis[J]. Ann Surg, 2021, 273(3): 587-594. DOI: 10.1097/SLA.0000000000003242
[17]	SHEN ZT, ZHOU H, LI AM, et al. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer[J]. J Cancer Res Clin Oncol, 2020, 146(2): 417-428. DOI: 10.1007/s00432-019-03066-z
[18]	ARCELLI A, GUIDO A, BUWENGE M, et al. Higher biologically effective dose predicts survival in sbrt of pancreatic cancer: A multicentric analysis (PAULA-1)[J]. Anticancer Res, 2020, 40(1): 465-472. DOI: 10.21873/anticanres.13975
[19]	ZHANG AM, CHANG XY, LI WG, et al. Clinical effect of CyberKnife radiosurgery in locally advanced pancreatic cancer or pancreatic cancer with distant metastasis[J]. J Clin Hepatol, 2019, 35(1): 143-146. DOI: 10.3969/j.issn.1001-5256.2019.01.027 张爱民, 常小云, 李文刚, 等. 射波刀治疗局部进展期及合并远处转移胰腺癌的效果分析[J]. 临床肝胆病杂志, 2019, 35(1): 143-146. DOI: 10.3969/j.issn.1001-5256.2019.01.027
[20]	SCORSETTI M, COMITO T, FRANCESCHINI D, et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question[J]. Br J Radiol, 2020, 93(1106): 20190627. DOI: 10.1259/bjr.20190627
[21]	SHI W, JIANG R, LIANG F, et al. Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer[J]. Cancer Manag Res, 2019, 11: 5065-5073. DOI: 10.2147/CMAR.S202543
[22]	LI Y, LIU W, ZHAO L, et al. The main bottleneck for non-metastatic pancreatic adenocarcinoma in past decades: A population-based analysis[J]. Med Sci Monit, 2020, 26: e921515.
[23]	KHATTAB A, PATRUNI S, ABEL S, et al. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma[J]. J Gastrointest Oncol, 2019, 10(5): 918-927. DOI: 10.21037/jgo.2019.07.02
[24]	GARNIER J, EWALD J, MARCHESE U, et al. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study[J]. BMC Cancer, 2020, 20(1): 203. DOI: 10.1186/s12885-020-6690-1
[25]	PARR E, DU Q, ZHANG C, et al. Radiomics-based outcome prediction for pancreatic cancer following stereotactic body radiotherapy[J]. Cancers (Basel), 2020, 12(4)L 1051. DOI: 10.3390/cancers12041051
[26]	SIMPSON G, SPIELER B, DOGAN N, et al. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study[J]. Med Phys, 2020, 47(8): 3682-3690. DOI: 10.1002/mp.14200
[27]	SU W, REN S, ZHU X, et al. Standardized thresholds of volume-based PET/CT parameters predicting survival of patients with pancreatic head cancer treated with stereotactic body radiation therapy[J]. Ann Nucl Med, 2020, 34(6): 379-387. DOI: 10.1007/s12149-020-01454-x
[28]	INCERTI E, VANOLI EG, BROGGI S, et al. Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients[J]. Nucl Med Commun, 2019, 40(10): 1072-1080. DOI: 10.1097/MNM.0000000000001065